Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (381-390 of 564) with videos related to

Pageof 57
Sort By:
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodologyM E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
The Lancet. Oncology|July 5, 2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsHai T Tran, Yuan Liu, Amado J Zurita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Future Oncology (London, England)|January 29, 2019
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationaleViktor Grünwald, Thomas Powles, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Pageof 57

Showing results (381-390 of 564) with videos related to

Sort By:
Pageof 57
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodologyM E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
The Lancet. Oncology|July 5, 2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsHai T Tran, Yuan Liu, Amado J Zurita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Future Oncology (London, England)|January 29, 2019
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationaleViktor Grünwald, Thomas Powles, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Pageof 57